Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Executive Summary

Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

You may also be interested in...



Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside

Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth

Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.

Industry Flying High With Record-Breaking First Novel Launch Tally in 2021

2021 was another record-breaking year for novel product launches as COVID-19 continued to make an impact, but the industry’s response to the pandemic did not fully account for the acceleration seen in this strict measure of R&D productivity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel